151 related articles for article (PubMed ID: 34580027)
21. Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Chen X; Yao J; Liu L; Zheng W; Hu X; Zhu Y; Wang H; Guo J
Target Oncol; 2019 Apr; 14(2):187-195. PubMed ID: 30887420
[TBL] [Abstract][Full Text] [Related]
22. Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Hamilton Z; Lee HJ; Jimenez J; Lane BR; Wang S; Beksac AT; Gillis K; Alagh A; Tobert C; Randall JM; Kane CJ; Millard F; Campbell SC; Derweesh IH
BJU Int; 2016 Dec; 118(6):927-934. PubMed ID: 27008916
[TBL] [Abstract][Full Text] [Related]
23. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
24. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
[TBL] [Abstract][Full Text] [Related]
27. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
29. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
Bedke J; Chun FK; Merseburger A; Scharpf M; Kasprzyk K; Schilling D; Sievert KD; Stenzl A; Kruck S
BJU Int; 2012 Dec; 110(11 Pt B):E771-7. PubMed ID: 23134582
[TBL] [Abstract][Full Text] [Related]
31. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
Derosa L; Bayar MA; Albiges L; Le Teuff G; Escudier B
Angiogenesis; 2019 Aug; 22(3):383-395. PubMed ID: 30739258
[TBL] [Abstract][Full Text] [Related]
32. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
[TBL] [Abstract][Full Text] [Related]
33. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY
Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963
[TBL] [Abstract][Full Text] [Related]
34. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Wells JC; Graham J; Beuselinck B; Bjarnason GA; Donskov F; Hansen AR; McKay RR; Vaishampayan U; De Velasco G; Duh MS; Huynh L; Nguyen C; Zanotti G; Ramaswamy K; Choueiri TK; Heng DYC
Clin Genitourin Cancer; 2020 Aug; 18(4):e350-e359. PubMed ID: 31926879
[TBL] [Abstract][Full Text] [Related]
36. The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma.
Mano R; Flynn J; Blum KA; Silagy AW; DiNatale RG; Marcon J; Wang A; Sanchez A; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
Urol Oncol; 2019 Dec; 37(12):916-923. PubMed ID: 31590969
[TBL] [Abstract][Full Text] [Related]
37. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.
Zurita AJ; Gagnon RC; Liu Y; Tran HT; Figlin RA; Hutson TE; D'Amelio AM; Sternberg CN; Pandite LN; Heymach JV
Br J Cancer; 2017 Aug; 117(4):478-484. PubMed ID: 28683470
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
39. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
40. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Margulis V; Shariat SF; Rapoport Y; Rink M; Sjoberg DD; Tannir NM; Abel EJ; Culp SH; Tamboli P; Wood CG
Eur Urol; 2013 May; 63(5):947-52. PubMed ID: 23273681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]